[[{“value”:”That is the topic of my latest Bloomberg column, here is one excerpt: From both a biomedical and economic point of view, the success of the new class of weight-loss drugs is something to behold. Not only are they a remarkable scientific achievement, but — in the case of Ozempic and Wegovy, both made by
The post Small countries, big firms appeared first on Marginal REVOLUTION.”}]]
That is the topic of my latest Bloomberg column, here is one excerpt:
From both a biomedical and economic point of view, the success of the new class of weight-loss drugs is something to behold. Not only are they a remarkable scientific achievement, but — in the case of Ozempic and Wegovy, both made by Novo Nordisk — they are a huge boon to the Danish economy. The Danish pharmaceutical industry kept Denmark from falling into a recession last year.
The dependence of some mid-sized economies on a single commodity, often related to oil or natural gas, is a familiar story. The new twist, which may become increasingly common, is a national economy dependent on a single company — not a natural resource. This will lead to some fundamentally new economic and political dynamics.
And:
Government attempts to manage a biomedical company, or a major AI company for that matter, would probably not work. Private-sector management thus becomes ever more important for the economic growth of these small to mid-sized countries.
And while it is better for a country to have one big, successful company than not, such a company — such as Nokia in Finland — does put the domestic economy in a somewhat precarious position. Politically as well, that company will have a fair amount of leverage over domestic decisions. It is noteworthy that Novo Nordisk has a very large philanthropic fund, worth more than $100 billion by one estimate. The mere option of spending some of that money in Denmark gives the company further influence over politics and public opinion.
The net result might be more “crony capitalism” — which, to be clear, is preferable to socialism — in mid-sized countries.
Abroad, as the demand for these weight-loss drugs continues to grow, people may start identifying Denmark with pharmaceuticals — just as many people identify France with wine or cheese. The longer-run image of Denmark may shift at home as well, perhaps in a manner that encourages further successes in the biomedical sector.
Worth a ponder, there is more at the link.
The post Small countries, big firms appeared first on Marginal REVOLUTION.
Current Affairs, Economics, Political Science, Uncategorized
Leave a Reply